JP2010536842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536842A5 JP2010536842A5 JP2010521488A JP2010521488A JP2010536842A5 JP 2010536842 A5 JP2010536842 A5 JP 2010536842A5 JP 2010521488 A JP2010521488 A JP 2010521488A JP 2010521488 A JP2010521488 A JP 2010521488A JP 2010536842 A5 JP2010536842 A5 JP 2010536842A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- independently
- tautomer
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 229910052760 oxygen Inorganic materials 0.000 claims 19
- 229910052717 sulfur Inorganic materials 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 4
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010057430 Retinal injury Diseases 0.000 claims 2
- 206010038997 Retroviral infections Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000009759 skin aging Effects 0.000 claims 2
- 230000037380 skin damage Effects 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 CC(C1CC(C*(*=C2)c(cccc3)c3C2=O)CCC1)=O Chemical compound CC(C1CC(C*(*=C2)c(cccc3)c3C2=O)CCC1)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0716532.7A GB0716532D0 (en) | 2007-08-24 | 2007-08-24 | Therapeutic compounds |
| PCT/GB2008/050731 WO2009027730A1 (en) | 2007-08-24 | 2008-08-21 | Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010536842A JP2010536842A (ja) | 2010-12-02 |
| JP2010536842A5 true JP2010536842A5 (enExample) | 2011-09-22 |
Family
ID=38599210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521488A Pending JP2010536842A (ja) | 2007-08-24 | 2008-08-21 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのキノリン−４−オン及び４−オキソジヒドロシンノリン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8354413B2 (enExample) |
| EP (1) | EP2193121A1 (enExample) |
| JP (1) | JP2010536842A (enExample) |
| AU (1) | AU2008291905A1 (enExample) |
| CA (1) | CA2697971A1 (enExample) |
| GB (1) | GB0716532D0 (enExample) |
| WO (1) | WO2009027730A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2590987T3 (es) | 2009-04-29 | 2016-11-24 | Glaxo Group Limited | Derivados de 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]pirazina como moduladores de P2X7 |
| EP2686305B1 (en) * | 2011-03-14 | 2020-09-16 | Impact Therapeutics, Inc. | Quinazolinediones and their use |
| TWI527800B (zh) | 2011-04-01 | 2016-04-01 | 南京英派藥業有限公司 | 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用 |
| SMT202000540T1 (it) | 2014-10-06 | 2020-11-10 | Vertex Pharma | Modulatori di regolatore di conduttanza transmembrana di fibrosi cistica |
| US10738030B2 (en) | 2016-03-31 | 2020-08-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| JOP20190042B1 (ar) | 2016-09-30 | 2021-08-17 | Vertex Pharma | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل |
| UY37513A (es) | 2016-12-09 | 2018-07-31 | Vertex Pharma | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| AU2018309043B2 (en) | 2017-08-02 | 2022-03-31 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CN110845425B (zh) * | 2019-11-07 | 2023-09-08 | 合肥工业大学 | 一种酞嗪衍生物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68917024D1 (de) | 1988-05-24 | 1994-09-01 | Kirin Brewery | 4(1H)-Chinolonderivate. |
| IL100555A (en) * | 1991-02-07 | 2000-08-31 | Hoechst Marion Roussel Inc | N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them |
| US5753674A (en) | 1991-10-22 | 1998-05-19 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents |
| CA2196795C (en) | 1994-08-12 | 2001-04-03 | Mark H. Skolnick | Method for diagnosing a predisposition for breast and ovarian cancer |
| US5589483A (en) | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| ES2108641B1 (es) | 1995-07-31 | 1998-08-16 | Menarini Lab | Sulfonimidas quinolonicas con accion antagonista de los leucotrienos. |
| ES2233671T3 (es) | 2000-08-08 | 2005-06-16 | Sanofi-Aventis | Derivados de benzimidazol, su preparacion y aplicacion en terapeutica. |
| CN100400518C (zh) | 2000-10-30 | 2008-07-09 | 库多斯药物有限公司 | 2,3-二氮杂萘酮衍生物 |
| DE60218458T2 (de) | 2001-05-08 | 2007-11-15 | Kudos Pharmaceuticals Ltd. | Isochinolinon derivate als parp inhibitoren |
| WO2003051879A1 (en) | 2001-12-14 | 2003-06-26 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
| EP1501822B1 (en) | 2002-04-30 | 2010-12-15 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| KR101146806B1 (ko) * | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | 프탈라지논 유도체 |
| BRPI0414136A (pt) | 2003-09-04 | 2006-10-31 | Aventis Pharma Inc | indóis substituìdos como inibidores de poli(adp-ribose) polimerase (parp) |
| MXPA06009701A (es) | 2004-02-26 | 2007-03-26 | Inotek Pharmaceuticals Corp | Derivados de isoquinolina y metodos de uso de los mismos. |
| JP2008510783A (ja) | 2004-08-26 | 2008-04-10 | クドス ファーマシューティカルズ リミテッド | ４−ヘテロアリールメチル置換フタラジノン誘導体 |
| EP1954274B8 (en) | 2005-11-10 | 2011-01-12 | ChemoCentryx, Inc. | Substituted quinolones and methods of use |
-
2007
- 2007-08-24 GB GBGB0716532.7A patent/GB0716532D0/en not_active Ceased
-
2008
- 2008-08-21 JP JP2010521488A patent/JP2010536842A/ja active Pending
- 2008-08-21 WO PCT/GB2008/050731 patent/WO2009027730A1/en not_active Ceased
- 2008-08-21 CA CA2697971A patent/CA2697971A1/en not_active Abandoned
- 2008-08-21 US US12/673,555 patent/US8354413B2/en not_active Expired - Fee Related
- 2008-08-21 AU AU2008291905A patent/AU2008291905A1/en not_active Abandoned
- 2008-08-21 EP EP08788702A patent/EP2193121A1/en not_active Withdrawn